DANDY® CELERY LAUNCHES 'SHUCK & SMILES' CONSUMER SWEEPSTAKES
Shucks & Smiles Sweepstakes
Find Dandy Sweet Corn at a grocery store near you!
Oviedo, Fla., May 13, 2025 (GLOBE NEWSWIRE) -- Dandy® Produce, a leading grower of fresh celery, radish and corn in the U.S., launches the 'Shucks & Smiles Sweepstakes'. Now through May 30, participants can enter for 31 chances to win different prize packs, including one grand prize valued at $670, five secondary prizes valued at $210 each and 25 third place winners who will receive free product and coupons.
At the end of the promotion, one lucky winner will be chosen to receive a brand name 22-inch griddle with grilling accessories, a variety of BBQ seasonings and rubs, along with a $250 gift card to a popular online grocery ordering and delivery service, and free Dandy corn sample coupons. Five additional winners will receive an 11-quart name brand cooler, pool float, insulated tumbler $50 online grocery and delivery service gift card as well as more Dandy corn products. The brand will also choose 25 winners to receive coupons to enjoy fresh corn even after the sweepstakes ends.
'This time of year, shoppers are looking for ways to enjoy more time outside with family and friends and that includes mealtimes. We want to inspire shoppers to fire up the grill and enjoy sweet corn all summer long,' said Nichole Towell, senior director of marketing and packaging procurement at Duda Farm Fresh Foods. 'While corn on the cobb is a traditional and timeless favorite, sweet corn is also extremely versatile and can be used in salads, dips, appetizers and even desserts.'
Sweet corn is a healthy whole grain that is high in fiber and low in fat, making it a nutritious addition to any meal. Grown in the Florida sunshine during the late spring, fresh sweet corn from the Sunshine State is a perfect choice for health-conscious consumers. Dandy® sweet corn is also grown in Georgia and Michigan for year-round availability. Shoppers have the convenient options of both bulk corn as well as a pre-shucked and pre-cut tray pack options to help reduce meal prep time and offer a bit more convenience to cater to their busy lifestyles.
For additional information, please visit www.dudafresh.com or follow Dandy Fresh Produce social media platforms for daily inspiration at Facebook, Twitter, and Instagram.
ABOUT DANDY® CELERYFor nearly 100 years, Duda Farm Fresh Foods has been a leading grower, shipper, processor and marketer of fresh vegetables and citrus, and now, extends the Duda family's legacy, delivering their farm-fresh products under the Dandy® brand to North America's restaurants and grocery stores. Known for their superior celery, the company has evolved their product assortment over the years to accommodate trends in health and wellness and to provide consumers value-added solutions that meet the needs for fresh and convenient meal and snack solutions. With primary locations in Florida, California, Arizona, Georgia and Michigan, Dandy® is committed to innovation and sustainability in every area of their business and remains focused on growing a healthy future for generations to come. For more information, please visit www.dudafresh.com.
Attachments
Shucks & Smiles Sweepstakes
Find Dandy Sweet Corn at a grocery store near you!
CONTACT: Nichole Towell Duda Farm Fresh Foods 561-804-1477 nichole.towell@duda.comSign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Entrepreneur
34 minutes ago
- Entrepreneur
სელფი მობაილი ZEG ფესტივალის პარტნიორია
საავტორო უფლება © 2025 Entrepreneur Media, LLC ყველა უფლება დაცულია. Entrepreneur® and its related marks are registered trademarks of Entrepreneur Media LLC
Yahoo
38 minutes ago
- Yahoo
ADC Therapeutics Announces Updated Data from LOTIS-7 Clinical Trial Presented at the European Hematology Association 2025 Congress
ZYNLONTA® in combination with glofitamab (COLUMVI®) in patients with r/r DLBCL demonstrated clinically meaningful benefit with overall response rate (ORR) of 93.3% and a complete response (CR) rate of 86.7% across 30 efficacy evaluable patients 25 of 26 patients achieving CR remained in CR as of the data cut-off Initial data show the combination is generally well tolerated with a manageable safety profile Company expanding enrollment for LOTIS-7 to 100 patients at 150 µg/kg dose Company to host conference call today at 8:00 a.m. ET/2:00 p.m. CEST LAUSANNE, Switzerland, June 12, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced updated data from the LOTIS-7 Phase 1b open-label clinical trial evaluating the safety and efficacy of ZYNLONTA® in combination with the bispecific antibody glofitamab (COLUMVI®) in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) to be presented at the European Hematology Association 2025 Congress (EHA2025) in Milan, Italy. The Company will host a conference call and webcast featuring LOTIS-7 trial principal investigator and EHA presenting author, Juan Alderuccio, MD, Clinical Site Disease Group Leader, Lymphoma Section, at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine today at 8:00 a.m. ET to discuss the results. To access the conference call, please register here. "The data seen in this study with the combination of ZYNLONTA and glofitamab has shown a manageable safety profile along with strong efficacy data from patients with relapsed or refractory DLBCL, with complete responses observed regardless of prior therapy, including CAR-T," said Mohamed Zaki, MD, PhD, Chief Medical Officer of ADC Therapeutics. "The combination of these two anti-cancer agents holds significant promise for advancing the treatment landscape and addressing unmet need in patients with these hard-to-treat lymphomas." The presentation highlights updated data as of April 14, 2025, in which r/r LBCL patients received dose levels of 120 µg/kg or 150 µg/kg of ZYNLONTA plus the bispecific antibody glofitamab, with 41 patients evaluable for safety and 30 patients evaluable for efficacy. Key highlights of the LOTIS-7 data presentation are as follows: Best overall response data among the 30 efficacy evaluable patients shows overall response rate (ORR) of 93.3% (28/30 pts) as assessed by Lugano Criteria Complete response (CR) rate of 86.7% (26/30 pts) Of these, 25/26 patients achieving CR remain in CR as of the data cut-off Median time to CR in 120 µg/kg = 80 days Median time to CR in 150 µg/kg = 42 days 12 patients converted from stable disease (SD) or partial response (PR) to CR over time (1 and 11 pts respectively) Of the 6 patients previously treated with CAR-T and undergoing response assessment, 5 achieved a CR Among the 41 safety evaluable patients, the combination was generally well tolerated with a manageable safety profile and no DLTs across dose levels Grade 3 or higher treatment emergent adverse events (TEAEs) observed in > 5% of patients included neutropenia (24.4%), anemia (9.8%), AST increased (7.3%), GGT increased (7.3%), and thrombocytopenia (7.3%) In the 150 µg/kg dose, cytokine release syndrome (CRS) (23.8%), all of which were Grade 1, and immune effector cell-associated neurotoxicity syndrome (ICANS) (4.8%), with one case of Grade 2, were observed In the 120 µg/kg dose, CRS all grades (55%), all of which were Grade 1/2 except one case of Grade 3, and ICANS (10%), with one case of Grade 1 and one case of Grade 2, were observed TEAEs leading to discontinuation included 3 each for ZYNLONTA and glofitamab There were no Grade 5 TEAEs observed "We believe these new data are differentiating and further reinforce the potential of ZYNLONTA plus the bispecific glofitamab to improve outcomes for DLBCL patients who need it most," said Ameet Mallik, Chief Executive Officer of ADC Therapeutics. "This early safety and efficacy data support the ongoing expansion of this study to 100 patients at the 150 µg/kg dose of ZYNLONTA plus glofitamab. We look forward to discussing the results with Dr. Alderuccio during our conference call today in addition to the presentation of the data set across two key conferences." This data will be shared at EHA2025 during a poster presentation on June 14 at 6:30 p.m. CEST and also as an oral encore presentation at the 18th International Conference on Malignant Lymphoma (ICML) in Lugano, Switzerland on Friday, June 20 at 9:00 a.m. ET. The Company plans to share additional data before the end of 2025. Conference Call InformationTo access the conference call, please register here. The participant toll-free dial-in number is 1-800-836-8184 for North America and Canada. It is recommended that you join 10 minutes before the event, though you may pre-register at any time. A live webcast of the call will be available under "Events and Presentations" in the Investors section of the ADC Therapeutics website at The archived webcast will be available for 30 days following the call. About LOTIS-7LOTIS-7 is a Phase 1b global multicenter, multi-arm study in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL) including Part 1 (dose escalation) and Part 2 (dose expansion). The three dosing arms include ZYNLONTA plus polatuzumab vedotin, ZYNLONTA plus glofitamab, and ZYNLONTA plus mosunetuzumab T-cell-engaging bispecific monoclonal antibodies (BsAbs). Enrollment in LOTIS-7 includes Part 1 of the study with a 3+3 dose escalation in 3L/3L+ heavily pre-treated patients with ZYNLONTA doses starting at 90 µg/kg and then proceeding to 120 µg/kg and 150 µg/kg. Part 2 includes dose expansion in 2L/2L+ large B-cell lymphoma in the ZYNLONTA plus glofitamab arm at dose levels determined from Part 1 (120 µg/kg and 150 µg/kg of ZYNLONTA plus the approved dosing of glofitamab). Primary endpoints of the study include safety and tolerability. Secondary efficacy endpoints include ORR, DOR, CRR, PFS, RFS, and OS as well as pharmacokinetics and immunogenicity. For more information about the LOTIS-7 trial, visit (NCT04970901). About ZYNLONTA® ZYNLONTA® is a CD19-directed antibody drug conjugate (ADC). Once bound to a CD19-expressing cell, ZYNLONTA is internalized by the cell, where enzymes release a pyrrolobenzodiazepine (PBD) payload. The potent payload binds to DNA minor groove with little distortion, remaining less visible to DNA repair mechanisms. This ultimately results in cell cycle arrest and tumor cell death. The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have approved ZYNLONTA (loncastuximab tesirine-lpyl) for the treatment of adult patients with relapsed or refractory (r/r) large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS), DLBCL arising from low-grade lymphoma and also high-grade B-cell lymphoma. The trial included a broad spectrum of heavily pre-treated patients (median three prior lines of therapy) with difficult-to-treat disease, including patients who did not respond to first-line therapy, patients refractory to all prior lines of therapy, patients with double/triple hit genetics and patients who had stem cell transplant and CAR-T therapy prior to their treatment with ZYNLONTA. This indication is approved by the FDA under accelerated approval and in the European Union under conditional approval based on overall response rate and continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. Please see full prescribing information including important safety information about ZYNLONTA at ZYNLONTA is also being evaluated as a therapeutic option in combination studies in other B-cell malignancies and earlier lines of therapy. About ADC Therapeutics ADC Therapeutics (NYSE: ADCT) is a commercial-stage biotechnology company helping to improve the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs). The Company is advancing its proprietary ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. ADC Therapeutics' CD19-directed ADC ZYNLONTA (loncastuximab tesirine-lpyl) received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents and in earlier lines of therapy. In addition to ZYNLONTA, ADC Therapeutics has multiple ADCs in ongoing clinical and preclinical development. ADC Therapeutics is based in Lausanne (Biopôle), Switzerland and has operations in London and New Jersey. For more information, please visit and follow the Company on LinkedIn. ZYNLONTA® is a registered trademark of ADC Therapeutics SA. Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the potential of ZYNLONTA® in combination with the bispecific antibody glofitamab, including the reproducibility and durability of any favorable results initially seen in patients dosed to date, and the Company's research, development and regulatory plans, including the timing and results of clinical trials and the timing and outcome of regulatory submissions. In some cases you can identify forward-looking statements by terminology such as "may", "will", "should", "would", "expect", "intend", "plan", "anticipate", "believe", "estimate", "predict", "potential", "seem", "seek", "future", "continue", or "appear" or the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to: whether future LOTIS-7 clinical trial results will be consistent with or different from the LOTIS-7 data presented at EHA and ICML and future compendia and regulatory strategy and opportunity; the expected cash runway into mid-2026 the Company's ability to grow ZYNLONTA® revenue in the United States; the ability of our partners to commercialize ZYNLONTA® in foreign markets, the timing and amount of future revenue and payments to us from such partnerships and their ability to obtain regulatory approval for ZYNLONTA® in foreign jurisdictions; the timing and results of the Company's or its partners' research and development projects or clinical trials including LOTIS 5 and 7, as well as early research in certain solid tumors with different targets, linkers and payloads; the timing and results of investigator-initiated trials including those studying FL and MZL and the potential regulatory and/or compendia strategy and the future opportunity; the timing and outcome of regulatory submissions for the Company's products or product candidates; actions by the FDA or foreign regulatory authorities; projected revenue and expenses; the Company's indebtedness, including Healthcare Royalty Management and Blue Owl and Oaktree facilities, and the restrictions imposed on the Company's activities by such indebtedness, the ability to comply with the terms of the various agreements and repay such indebtedness and the significant cash required to service such indebtedness; and the Company's ability to obtain financial and other resources for its research, development, clinical, and commercial activities. Additional information concerning these and other factors that may cause actual results to differ materially from those anticipated in the forward-looking statements is contained in the "Risk Factors" section of the Company's Annual Report on Form 10-K and in the Company's other periodic and current reports and filings with the U.S. Securities and Exchange Commission. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance, achievements or prospects to be materially different from any future results, performance, achievements or prospects expressed in or implied by such forward-looking statements. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this document. CONTACTS:Investor RelationsMarcy GrahamADC 650-667-6450 Media RelationsNicole RileyADC 862-926-9040 View original content to download multimedia: SOURCE ADC Therapeutics SA Sign in to access your portfolio
Fast Company
an hour ago
- Fast Company
Thanks to AI, the one-person unicorn is closer than you think
When Mike Krieger helped launch Instagram in 2010 as a cofounder, building something as simple as a photo filter took his team weeks of engineering time and tough trade-offs. Now, as chief product officer at Anthropic, he's watching early-stage startup founders accomplish far more in far less time—sometimes over a single weekend. Thanks to intuitive agentic AI models (or AI agents), founders are experimenting with product, code, and business strategies, often without needing to hire specialized team members. 'When I think back to Instagram's early days, our famously small team had to make painful decisions—either explore adding video or focus on our core creativity,' Krieger tells Fast Company. 'With AI agents, startups can now run experiments in parallel and build products faster than ever before.' To him, it signals a seismic shift: the rise of agentic entrepreneurship. Enterprises can supercharge engineering teams while individuals with bold ideas but no technical background can finally bring their visions to life. 'At Anthropic, 90% of Claude's code is now written by AI, and this has completely transformed how we build products. Recently, Claude helped me prototype something in 25 minutes that would have taken me six hours,' Krieger says. 'I see founders who tried every model, couldn't get their startup to work, then with Claude, their startup suddenly works.' Krieger believes agentic AI is fundamentally redefining what it means to be a founder. You no longer need to write code or raise significant capital to start building. The bottlenecks, he says, have shifted to decision-making and operational friction—like managing merge queues. And the numbers support this momentum. In its first week of launch, Claude 4 reportedly tripled Anthropic's subscriber base and now accounts for more than 60% of the company's API traffic. Usage of Claude Code, its specialized AI coding agent, has spiked nearly 40%, drawing interest from both developers and nontechnical builders. Krieger shared that some users have even begun treating AI agents less like tools and more like capable creative collaborators. 'AI models can now function like an entry-level worker, and that is going to have a big impact on the workforce. We think we need to talk about this so we can prepare our economy and our society for this change, which is happening very fast,' he says. 'It's too late to stop the train—but we can steer it in the right direction.' A few weeks ago, Anthropic CEO Dario Amodei predicted that 'the first one-employee billion-dollar company' could emerge as soon as 2026, enabled by AI. He also suggested AI could eliminate half of all entry-level jobs within the next five years—a claim that drew immediate pushback from some in the tech industry. Among the skeptics was Google CEO Sundar Pichai, who cautioned against overestimating the reliability of AI systems like Gemini. 'Even the best models still make basic mistakes,' Pichai said during the recent Bloomberg Tech Summit in San Francisco. 'Are we currently on an absolute path to AGI? I don't think anyone can say for sure.' On the prospect of AI displacing the workforce in the near future, Pichai remained measured. 'We've made predictions like that for the last 20 years about technology and automation,' he said. 'And it hasn't quite played out that way.' Yet even amid skepticism, a quieter revolution is unfolding beneath the surface of agentic AI—one that's reshaping how work itself is defined in the era of intelligent software collaborators. MCP: The Infrastructure That Makes AI 'Work' The unsung hero behind Anthropic and Claude's leap in capability isn't just the model itself—it's the Model Context Protocol (MCP). While Claude 4 is praised for its intelligence and natural language fluency, MCP is the system-level breakthrough that enables it to move from passive assistant to active collaborator. This open standard allows Claude's AI agents to securely interface with tools like GitHub, Stripe, Webflow, Notion, and even custom internal systems. As a result, Claude isn't limited to answering prompts. It can pull real-time analytics, trigger actions, update databases, launch web assets, and manage entire project pipelines. Just as http enabled browsers to interact with websites, MCP is creating a universal interface layer for AI agents to operate across digital tools. 'Previously, AI agents were largely isolated—they could process information you gave them, but they couldn't directly interact with your actual tools and systems,' Krieger says. 'By solving the connection problem together, we're building infrastructure that will unlock entirely new possibilities for human-AI collaboration, making AI systems dramatically more useful and relevant in real-world contexts.' Major tech companies are already integrating MCP. Microsoft has built it into Windows 11, Azure, and GitHub, allowing AI agents to run workflows across OS and cloud infrastructure. Google has added it to Gemini SDKs to bridge model interactions with live apps. Companies like Novo Nordisk, GitLab, Lyft, and Intercom are also deploying Claude agents into live workflows. In this light, Amodei's 'one-person unicorn' prediction seems less like hype and more like a reflection of a deeper platform shift. 'As developers build new connections between knowledge bases, development environments, and AI assistants, we're seeing the early emergence of the more connected AI ecosystem we envisioned,' Krieger says. 'As AI assistants become more agentic, MCP will evolve to support increasingly sophisticated workflows. [MCP] might be the most important thing Anthropic has ever shipped.' Agentic AI Is Redefining the Modern Startup Tech Stack Krieger sees the combination of Claude 4 and MCP as a genuine platform shift—one where the AI acts like a partner rather than just a productivity tool. He describes Claude Opus 4 as Anthropic's most powerful agentic model yet and the world's best coding model. '[Opus 4] can work autonomously for nearly seven hours, which transforms how teams approach work. When I can prototype something in minutes, that fundamentally changes what's possible for a single person,' Krieger says. 'In my experience, it mirrors how people manage their work. That level of autonomous task execution just wasn't possible before.' With MCP in play, Claude becomes more than an assistant. It can push code, analyze logs, manage documentation, and send updates—without the constant context switching that slows teams down. In some cases, Krieger says, it simulates workflows that once required coordination across multiple departments. 'When you can iterate at speed, every manual process, every unnecessary meeting becomes this jarring interruption,' he noted. Still, not everyone is convinced that AI-powered unicorns are imminent. Analysts caution that while AI agents can automate many workflows, they can't yet match the experience seasoned professionals bring. 'The state of LLM-based AI agents is that you must give them simple decisions to make to reliable answers. We are not close to being able to throw a bunch of data at an AI agent and trust its decision,' Tom Coshow, a senior director analyst at Gartner, tells Fast Company. 'Is there an automatic VP of sales ready to go? Not even close.' Coshow emphasizes the need for realistic expectations. 'It's important to get real about what you can and can't build,' he says. 'No-code design is incredibly powerful, but it also creates this illusion that anything you type into the box will just magically work. It doesn't.' Building robust AI agents for real-world business use, he explains, is far from trivial, noting, 'Complex agents are hard to get right. LLMs are inherently probabilistic, and most business processes simply can't rely on that kind of unpredictability.' A Brave New Startup Era? Anthropic's core bet reflects its broader philosophy: We're moving toward a world where major chunks of work are automated. 'It's better to be aware of the risk and adjust to the change than to take the chance and be caught unprepared,' Krieger says. 'We're seeing this shift begin with tech companies, but it's going to move quickly into other knowledge-intensive industries.' So, is the one-person unicorn just hype—or a sign of things to come? It may still be too early to know. For experts like Coshow, the future lies not in abrupt disruption, but in careful evolution. 'The path forward is well-designed agentic workflows with a human in the loop,' he says. Whether or not a billion-dollar solo startup emerges by 2026, the tools to build one are already here. And that, as Krieger sees it, changes everything. 'It's going to be about finding people who can work at the intersection of customer problems and AI capabilities,' he says. 'The most valuable early hire might not be a traditional engineer—it could be someone who translates needs into iterative, AI-powered solutions. The one-person unicorn will be relentlessly curious, and fluent in working with intelligent collaborators.'
